XVII.e

Pneumocystis jiroveci pneumonia

The incidence of Pneumocystis pneumonia is increasing (PMID23622345), as more patients with autoimmune- (especially granulomatous polyangiitis-WG), rheumatic and inflammatory conditions including IBD are being exposed to prolonged corticosteroid therapy and immunosuppressive agents. In addition to the risk in transplant recipients and in patients with solid or liquid malignacies (PMID 12974789). Prophylaxis should be discussed on a case by case basis in any patient potentially at risk (PMID 20360202), as Pneumocystis jiroveci pneumonia carries an ominous prognosis in the immunodepressed.with up to 60% mortality (See also under XIp and XIq). Quantitative PCR for Pneumocystis may help separate colonization from an infection (PMID 23990137). Prophylaxis reduces but does not completely eliminate the risk of Pneumocystis pneumonia (PMID 12974789)

Last update : 07/02/2015
 

Causative drugs

32